

          -  Pregnant or breastfeeding, or intending to become pregnant or father children within
             the projected duration of the trial from screening until 3 months following last dose.

          -  Is currently participating in or has participated in a study with an investigational
             product within 30 days preceding Day 0.

          -  Previous exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or
             receipt of an investigational vaccine product for the prevention of COVID-19, middle
             east respiratory syndrome (MERS) or severe acute respiratory syndrome (SARS).

          -  Current or history of the following medical conditions:

               -  Respiratory diseases

               -  Hypertension

               -  Malignancy within 5 years of screening

               -  Cardiovascular diseases

          -  Immunosuppression as a result of underlying illness or treatment including:

               -  Primary immunodeficiencies

               -  Long term use (>=7 days) of oral or parenteral glucocorticoids

               -  Current or anticipated use of disease-modifying doses of anti-rheumatic drugs
                  (and biologic disease-modifying drugs

               -  History of solid organ or bone marrow transplantation

               -  Prior history of other clinically significant immunosuppressive or clinically
                  diagnosed autoimmune disease

          -  Fewer than two acceptable sites are available for intradermal (ID) injection and
             electroporation (EP) considering the deltoid and anterolateral quadriceps muscles.

          -  Any physical examination findings and/or history of any illness that, in the opinion
             of the study investigator, might confound the results of the study or pose an
             additional risk to the patient by their participation in the study.
      